Business ❯ Pharmaceutical Industry ❯ Market Competition

Pricing Strategies

Direct-to-Consumer Sales Consumer Access Novo Nordisk GLP-1 Drugs Eli Lilly Executive Orders Regulatory Actions Pharmacy Benefit Managers Compounded Drugs Generic Drugs Novo Nordisk and Eli Lilly Product Launches Vaccine and Drug Development Consumer Impact Copycat Drugs Supply Chain Management CVS Health Cost Reduction

Novo Nordisk to Cut U.S. List Prices for Wegovy, Ozempic and Rybelsus to $675 in 2027

The move aims to lower out-of-pocket costs for insured patients whose payments are tied to list prices.

Indiana Sues Eli Lilly, Alleging Scheme to Inflate Insulin Prices

Lilly Cuts Zepbound Cash Prices on LillyDirect as GLP‑1 Price Competition Deepens